Leisure Capital Management Gilead Sciences, Inc. Transaction History

Leisure Capital Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	BUY	$76.01 - $86.7 $4,028 - $4,595	53 Added 0.31%	17,385 $1.34 Million
Q1 2023 Apr 27, 2023	BUY	$77.31 - $88.08 $1.12 Million - $1.27 Million	14,425 Added 496.22%	17,332 $1.44 Million
Q4 2022 Jan 27, 2023	BUY	$62.32 - $89.47 $181,164 - $260,089	2,907 New	2,907 $249,000
Q1 2022 May 12, 2022	SELL	$57.92 - $72.58 $168,025 - $210,554	-2,901 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $188,216 - $213,629	2,901 New	2,901 $211,000
Q2 2021 Aug 06, 2021	SELL	$63.47 - $69.35 $206,214 - $225,318	-3,249 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $30,000 - $34,230	-500 Reduced 13.34%	3,249 $210,000
Q4 2020 Feb 12, 2021	BUY	$56.65 - $64.55 $212,380 - $241,997	3,749 New	3,749 $218,000
Q3 2020 Oct 23, 2020	SELL	$62.1 - $78.08 $170,712 - $214,641	-2,749 Closed	0 $0
Q1 2020 May 07, 2020	BUY	$62.63 - $80.22 $172,169 - $220,524	2,749 New	2,749 $206,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Leisure Capital Management, based on Form 13F filings with the SEC.

Stay updated on Leisure Capital Management with notifications on news.